Amgen Faces Revenue Growth-But-Earnings Decline Conundrum

Amgen, a leading biotechnology company, has announced its revenue growth expectations for the year. According to Pluang, Amgen is anticipating a 2.9% increase in revenue but a significant drop of 7% in earnings per share. This development comes as a surprise, given the industry's overall trend.

The exact reasons behind this disparity are not clear, but analysts will be closely watching how Amgen navigates this situation. As the company continues to grow and expand its operations, investors will be keeping a close eye on any potential risks or challenges that may arise.